Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Reassessing the risk from rabies: A continuing threat to the UK?

Ashley C. Banyard\textsuperscript{a,\星}, Matt Hartley\textsuperscript{b}, Anthony R. Fooks\textsuperscript{a,\星}

\textsuperscript{a} Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency, Weybridge, Addlestone, Surrey KT15 3NB, UK
\textsuperscript{b} Veterinary Science Team, Area 5E, Defra, Nobel House, 17 Smith Square, London SW1P 3JR, UK
\textsuperscript{c} The National Centre for Zoonosis Research, University of Liverpool, Leahurst, Chester High Road, Neston CH64 7TE, UK

1. Introduction

To the developed world, rabies remains a largely neglected disease. Highly efficacious vaccines are available and in the event of an unvaccinated individual becoming exposed, prompt application of recommended procedures prior to clinical disease will avoid fatalities. The UK has had a rabies-free status for over 100 years, maintained by bio-security measures, rigorous public health management systems and more recently through the implementation of the Pet Travel Scheme (PETS) with retention of quarantine rules, in existence since 1901, for non-PETS animals. Even with these measures in place, the threat of re-introduction of the virus still exists on three levels. Firstly, the legal and illegal importation of live animals into the UK poses a threat, especially with the increased movement of human populations from areas of endemicity both within Europe and outside of the European Union (EU) into the UK. Secondly, the indigenous bat population is known to carry a virus genetically related to rabies virus, the European bat lyssavirus (EBLV). Molecular characterization of this virus has further characterized it as being EBLV type 2, genetically distinct from a similar virus that has caused several human deaths across Europe. Finally, a lack of awareness of the threat of rabies and related viruses to travelers visiting endemic areas also constitutes a re-introduction threat to the UK population. This review will address the most recent cases of lyssavirus infection, in both humans and animals, either contracted within the UK or from abroad. We highlight the current diagnostic necessity for testing indigenous and foreign cases and comment on current UK government policy in light of a European call to harmonise rabies legislation across Europe.

2. Rabies in the UK: history and current legislation

Historically, rabies is one of the most feared viruses of man. Late stage disease often includes aggression, delirium, convulsions and invariably death, the imagery behind public perception of the disease. The discovery of a number of related viruses, almost all isolated from bat species across the world, has seen the interest in this small group of viruses increase within the scientific community. Of course the island nation status of the UK has enabled
freedom from this terrifying disease for decades. In the 19th century rabies was widespread in the United Kingdom. The disease was maintained in packs of stray dogs with wildlife involvement remaining unreported. In the period 1886–1903 there were 3056 cases of dog rabies and more than 160 human deaths (Fooks et al., 2004a). The ‘General Rabies Order’, 1897 gave powers to the Board of Agriculture to enforce muzzling of dogs in specified districts and destruction of strays. These measures were highly effective with the last indigenous case occurring in Wales in 1902 (Fooks et al., 2004a).

2.1. Quarantine measures

To prevent recurrence of widespread disease, the Importation of Dogs Act of 1901 required imported dogs to be isolated at an approved kennels for a period of six months. Official quarantine measures were tightened further for dogs in 1922 and cats in 1928. The purpose of quarantine was so that rabies can be detected, contained and eliminated in controlled conditions with minimal risk of transmission to humans, domestic animals and wildlife. This stringent disease control method has been highly effective in protecting both the human and animal populations of Britain from rabies. Since 1922, there have been twenty-seven cases of rabies that have been confirmed and controlled (Fooks et al., 2004a). In 1969, a dog imported from India died of rabies in quarantine and in the same year two dogs, which had been released from the same quarantine station as the original dog, also died. This led to the introduction of the administration of rabies vaccine to all animals either prior to or on entering quarantine (Fooks et al., 2004a).

Since the introduction of quarantine rules there has only been one outbreak of rabies. This occurred between 1918 and 1922 originating from dogs smuggled into the country by returning First World War servicemen. Three hundred and twelve dogs, eight cats, two sheep, three pigs and three horses were infected. Rabies was eliminated through muzzling and leashing restrictions and the destruction of stray dogs (Fooks et al., 2004a). This outbreak demonstrated the importance of border controls and enforcement of import restrictions from countries with high levels of endemic disease.

Seventy-five years after the introduction of quarantine for pet animals, in 1997, the UK government initiated a review of the use of quarantine rules recognising that other countries such as Sweden and Australia were utilising alternative systems successfully. An enquiry chaired by Professor Ian Kennedy published a report ‘Quarantine and Rabies – a reappraisal’ in 1998 making 41 broad recommendations. In response to this, new legislation was developed that established the PETS scheme.

There remains complex legislation and a network of enforcement agents that continue to protect the UK from this most serious disease. The main domestic provisions are provided by The Rabies Importation of Dogs, Cats and Other Mammals Order 1974 which implements a number of European directives. This legislation controls the landing of ten orders of susceptible mammals ranging from elephants to primates. All imported animals are required to enter the country at designated seaports and airports. After landing they must be moved, by authorised carriers and in approved transportation, to registered quarantine premises (which is under the supervision of an official veterinarian), where they must remain for 6 months.

Special provisions based on risk have been made for some species. Vampire bats are placed in quarantine for life. This is because the vampire bat is one of the most important vectors of rabies to humans and mortality in the bats is low. Therefore, there is a risk that vampire bats may be persistently infected (McColl et al., 2000; Aguilar-Setien et al., 2005), however, no vampire bats have ever been imported into the UK.

Rodents and lagomorphs are exempt when they are destined to a facility licensed under the ‘Animal Scientific Procedures Act’ of 1986 or the ‘Zoo Licensing Act’ of 1981. Livestock species (bovines, ovines, caprines, swine) and horses are permitted to move between European Member States through the use of official health certification, which removes the need for quarantine. Elephants and animals of the order Artiodactyla (pigs, sheep, goats, cattle, camels, hippopotamuses and others) imported from outside the EU must be kept at the place of destination for 30 days and may only be released by an authorised officer. These lesser requirements reflect the unlikelyhood of these species transmitting rabies to humans or other animals.

These regulations were recently tested with the case of a consignment of young dogs being imported from Sri Lanka. In April 2008, a group of five stray dogs were being housed under current quarantine regulations at a quarantine centre in North East London. Nine days after arriving at the centre, one of the five dogs died and tested strongly positive for rabies antigen in a brain sample submitted to the Veterinary Laboratories Agency (VLA). This finding immediately led to a full public investigation trying to track all who may have come into contact with the infected animals, and arranging rabies post-exposure prophylaxis (PEP) where necessary. Vaccination status of those reported to have had contact with the puppy varied enormously with several individuals having had no pre-immunisation against the virus (Fooks et al., 2008).

This was the first case of rabies in quarantine in the UK for over 18 years. As this occurred inside a quarantine facility the ‘rabies-free’ status of the UK was unaffected. Variation in pre-exposure immunity among those involved in handling the infected animals highlighted the importance of ensuring that all persons who regularly handle imported animals receive complete rabies pre-exposure immunisation: generally three doses of rabies vaccine (on days 0, 7 and 28) followed by a booster at 1 year. During this incident, rapid laboratory diagnosis, close inter-agency working between Department for Environment, Food and Rural Affairs (Defra), the Department of Health (DoH) and the Health Protection Agency (HPA), and a prompt operational response at local level, permitted the timely identification of those who had at-risk contact with the rabid puppy and the initiation of appropriate PEP.

Quarantine requirements are still in force for all rabies susceptible animals other than domestic pet dogs, cats and ferrets that can enter the UK under the PETS regulations. It is important to note that if animals are proved to be non-compliant with the PETS regulations the animal will be required to enter quarantine for 6 months. Whilst the 6-month quarantine period is currently maintained, many commentators believe that 6 months is a disproportionate waiting period and that three months may be sufficient.

2.2. Animals leaving and re-entering the UK

The PETS travel scheme was initiated in the UK on 28th February 2000. This scheme served to allow fluidity of companion animal movement within qualifying countries for those that are able to fulfill various requirements regarding health and vaccination status. Initially only the 22 European Member States were able to use PETS enabling movement of animals into the UK although now several other countries qualify under the scheme, including Andorra, Gibraltar, Iceland, Liechtenstein, Luxembourg, Monaco, Norway, San Marino, Sweden and the Vatican.

Several requirements have to be met for animals to qualify for travel to and from the UK to these countries, including microchipping of pets, rabies vaccination and blood testing to assess suitable antibody titres within rabies vaccinated animals. On completion of these requirements owners are presented with a PETS certificate and are able to transport their animals out of, and back into, the UK. PETS certificates are valid for a period of six months after serological
testing until the next date that a rabies booster vaccination is due. Furthermore, before allowing re-entry of certificated animals into the UK, owners are required to gain another certificate to show that their animals have been treated for tick and tapeworm infestation between 24 and 48 h before airport or seaport check-in. Owners are also required to sign a declaration that their animals have not been outside of any qualifying countries during the previous 6 months.

In 2001, a number of island nations that had ‘rabies-free’ status were included in the scheme, greatly increasing the number of holiday destinations that people could travel to, accompanied by their animals. While PETS has proved hugely successful in allowing certificated vaccinated animals to move between rabies-free areas, quarantine regulations are still enforced for importations from endemically infected areas.

### 2.3. Animal importation

There are extensive powers provided to enforcement agencies to ensure that the UK and the EU remain protected from rabies. Live animal imports from countries outside the EU must enter at a specified border inspection post and be examined by a veterinary officer. If these examinations reveal that an animal is likely to constitute a danger to animal or human health the animal may be seized and destroyed. Illegal consignments are placed in quarantine, or if these examinations reveal that an animal is likely to constitute a danger to animal or human health the animal may be seized and destroyed. Illegal consignments are placed in quarantine, or re-dispatched outside the territory of the European Community. Unintentional imports also occur with animal stowaways being discovered at seaports and airports. These animals should also be submitted to complete quarantine.

Currently, the UK imposes stricter rules on pet travel compared to most other European states. The UK and other EU member states (Finland, Ireland, Malta and Sweden), impose heightened requirements for animals to be assessed serologically to confirm rabies vaccination as well as being certified as having been treated for potential tick and tapeworm infestation prior to entry into the UK. This increased requirement may soon, however, be reduced as derogations in place to sustain these rules are due to expire in December 2011. Whilst it seems inevitable that the current derogation will end, the proposed alteration to current legislation needs to ensure that both public and animal health are safeguarded as we move towards the elimination of terrestrial rabies across the EU.

### 2.4. UK bats and rabies: the European bat lyssaviruses

The discovery of European bat lyssavirus (EBLV) type-2 in a Daubenton’s bat (Myotis daubentonii) in 1996 in East Sussex fuelled concerns that bat rabies may be present within the UK and that there was a real threat of rabies entering the UK via migratory bats (Whitby et al. 2000). Following numerous cases of lyssavirus positive bats across Europe it is now accepted that bat lyssaviruses are endemic within UK and European bat populations. Cases of lyssavirus infection of both bats and incidences of spill-over infection from bats into humans and terrestrial wildlife species continue to occur, albeit rarely, across Europe. The majority of cases of EBLV-1 have been reported in Serotine bats (Eptesicus serotinus) (Fooks et al., 2003a), although a number of other species are susceptible to infection (Vazquez-Moron et al., 2008; Muller et al., 2007). Furthermore, EBLV-1 infection has also been reported in spill-over events, in incidental hosts including a stone marten, sheep and humans (Muller et al., 2004; Ronsholt, 2002; Selimov et al., 1989) with seropositivity and antigen detection in domestic cats also being reported (Dacheux et al., 2009; Bourhy et al., 2005; Tjornehoj et al., 2004). In comparison to EBLV-1, EBLV-2 has been reported on fewer occasions, having been detected in both Daubenton’s bats (Myotis daubentonii), native to the UK and pond bats (Myotis dasycneme), a European species occasionally found in the UK. As well as having been isolated in the UK, EBLV-2 isolates have also been reported in Switzerland, Holland, Germany and Finland (Lumio et al., 1986; Van der Poel et al., 2005; Muller et al., 2007; Freuling et al., 2008; Jakava-Viljanen et al., 2010).

Since 1996, EBLV-2 has been detected in several locations across the UK suggesting that EBLV-2 is endemic at a low level in British bats. Most recently, live EBLV-2 virus was isolated from a Dauben-ton’s bat in Scotland (Horton et al., 2009) (Table 1). As a result of EBLV isolation from UK bats, the VLA undertakes passive surveillance on all bats submitted to regional and national laboratories. Bat groups, such as the Bat Conservation Trust as well as other bat enthusiast groups, and members of the public are requested to be aware of, report and submit for testing any grounded bats, bats found dead or those acting unusually. Whilst a number of different infectious agents are known to infect bats, testing for lyssaviruses is of paramount importance due to the potential impact on human health.

Both passive and active surveillance strategies have been implemented and annually large numbers of bats are submitted for testing (Harris et al., 2006). Passive surveillance testing of UK bats started in 1987 and since then, up to and including 2009, a total of 10,340 bats have been submitted for testing for lyssavirus infection. This initiative has enabled detection of nine lyssavirus antigen-positive bats as well as identification of roosts, which required further investigation to assess seroprevalence. Of this total, a small percentage were Daubenton’s bats (2.7%), the suggested primary host for EBLV-2 and even fewer were Serotine bats (1.2%), the suggested host for EBLV-1 (Fig. 1). The majority of bats submitted for testing are Common Pipistrelle bats (72.5%), although to date there

### Table 1

Cases of EBLV-2 across Europe.

| Year | Location             | Virus reference | Bat specie | Reference               |
|------|----------------------|-----------------|------------|-------------------------|
| 1985 | Finland              | RV8             | Human      | Lumio et al. (1986)     |
| 1987 | Tjerkwerd, The Netherlands | RV29         | M. dasycneme | Van der Poel et al. (2005) |
| 1989 | The Netherlands      | RV228           | M. dasycneme | Van der Poel et al. (2005) |
| 1989 | Switzerland          | RV594           | M. daub.    | Lumio et al. (1986)     |
| 1989 | Switzerland          | RV621           | Unknown sp. | Lumio et al. (1986)     |
| 1996 | New Haven, Sussex    | RV268           | M. daub.    | Whitby et al. (2000)    |
| 2002 | Carnforth, Lancashire| RV1332          | M. daub.    | Johnson et al. (2003)   |
| 2002 | Angus, Scotland      | RV1333          | Human      | Fooks et al. (2003c)    |
| 2004 | Staines, Surrey      | RV1787          | M. daub.    | Fooks et al. (2004b)    |
| 2004 | Blackburn Lancashire | RV1788          | M. daub.    | Fooks et al. (2004b)    |
| 2006 | Abington, Oxfordshire| RV2159          | M. daub.    | Fooks et al. (2006)     |
| 2007 | Stokesay Castle, Shropshire | RV2336   | M. daub.    | Harris et al. (2007)    |
| 2007 | Germany              | n/a             | M. daub.    | Freuling et al. (2008)  |
| 2008 | Teddington, Surrey   | RV2418          | M. daub.    | Pajamo et al. (2008)    |
| 2008 | Stokesay Castle, Shropshire | RV2473  | M. daub.    | Banyard et al. (2009)   |
| 2009 | West Lothan, Scotland| RV2482          | M. daub.    | Horton et al. (2009)    |
| 2009 | Finland              | n/a             | M. daub.    | Jakava-Viljanen et al. (2010) |
From a geographical point of view, the UK population of Serotine negative for lyssavirus infection by fluorescent antibody test (FAT). Examined through the passive surveillance scheme and all were interestingly, between 1987 and 2009, 129 Serotine bats were much greater seroconversion levels were reported (Perez-Jorda et al., 1995; Vazquez-Moron et al., 2008; Serra Cobo et al., 2002). This initiative sampled 273 Serotine bats and 363 neutralising antibodies and viral RNA or infectious virus in saliva, oropharyngeal swabs were taken for the detection of EBLV-specific antibodies. As well as passive surveillance of bat populations, active surveillance initiatives have also been undertaken. Between 2003 and 2006, the VLA, in collaboration with Scottish Executive, Scottish Natural Heritage, and Defra undertook targeted surveillance for European bat lyssaviruses throughout Scotland and England, focusing on the two bat species most likely to host these viruses, Daubenton’s and Serotine bats (Harris et al., 2009). Blood and oropharyngeal swabs were taken for the detection of EBLV-specific neutralising antibodies and viral RNA or infectious virus in saliva, respectively. This initiative sampled 273 Serotine bats and 363 Daubenton’s bats with the conclusion that, in the populations tested, there was an EBLV-2 antibody prevalence of 1.0–4.1% (95% CI, mean = 2.2%). Interestingly, EBLV-1-specific antibodies were only detected from one sample in a Serotine bat. The seroprevalence of EBLV-2 within Daubenton’s bats reported in this study is very low compared to data from Spanish bat populations where much greater seroconversion levels were reported (Perez-Jorda et al., 1995; Vazquez-Moron et al., 2008; Serra Cobo et al., 2002). This study proved that EBLV-2 infection is maintained in Daubenton’s bat populations in the UK. The detection of only a single Serotine bat with EBLV-1-specific antibodies suggests that it is unlikely that EBLV-1 circulates in this species in England (Harris et al., 2009). Interestingly, between 1987 and 2009, 129 Serotine bats were examined through the passive surveillance scheme and all were negative for lyssavirus infection by fluorescent antibody test (FAT). From a geographical point of view, the UK population of Serotine bats seems to be restricted to southern England, often roosting in residential properties. The species is one of the least common in the UK with an estimated population of less than 15,000 individuals. With transmission of virus often linked to the availability of new vectors, it is thought that low numbers of Serotine bats in the UK may preclude maintenance of EBLV-1 in UK roosts (Harris et al., 2009).

The threat to the UK population posed by these viruses remains low. It is essentially unknown whether or not EBLV-1 will enter the UK bat population in future and increase this threat. Furthermore, maintenance of these viruses within bat populations is very poorly understood, as is the case for all other lyssavirus infections in bats, and a greater understanding of bat populations and ecology is required to answer questions that remain. Also, the apparent restricted infection of certain bat species in the UK and Europe is not understood. It is known that in the UK, Daubenton’s bats co-roost with other species yet EBLV-2 infection of other UK bats has not been detected. The threat of EBLV-2 spill-over into the human population remains, however, and with at least one human death attributed to infection with this virus, the risk is not to be ignored.

2.5. Rabies and travel

Generally, the threat of rabies virus infection to travelers from the UK is low. However, for individuals who choose to travel to rabies endemic areas the risk is increased and in recent years there have been several tragic cases of individuals being exposed to rabies virus abroad. Where PEP was not administered, human deaths have occurred upon return to the UK. Incubation periods following exposure are variable and whilst often clinical disease ensues soon after infection, in some instances the incubation period can be considerably longer. The recent case of a 37-year-old woman from Northern Ireland dying from rabies virus infection following an incubation period of what may be up to 2 years illustrates this point. In this instance, the individual in question did not seek medical attention following an incident with aggressive dogs in South Africa (Hunter et al., 2010). Human rabies cases in the UK where exposure occurred abroad over the last 10 years are detailed in Table 2. A similar situation exists across Europe. The recent death of a Dutch traveler from infection with Duvenhage virus, a virus closely related to rabies virus, further illustrates the potential danger of these viruses to travelers. Here, a bat had flown into the face of a 34-year-old woman and very small puncture marks were identified on her face. Whilst the wound was washed with both detergent and alcohol swabs, PEP was not administered and 23 days after coming into contact with the bat, symptoms of clinical disease started to develop (van Thiel et al., 2008).

A recent study in France evaluated cases of international travelers exposed to potentially rabid animals. The study highlights the fact that the majority of cases were reported from North Africa (41.5%) and Asia (22.2%) and a lack of awareness when seeking medical advice regarding vaccinations. Indeed in those countries where at-risk injuries were recorded (Algeria, Morocco, Tunisia, Thailand, and Turkey), travelers do not usually seek advice from specialized travel clinics, as the areas involved are not at risk for specific travel-associated diseases like malaria or yellow fever. Interestingly, a correlation between the likelihood of being bitten by a certain animal species was made, with dogs being more frequently involved in Algeria, cats in Tunisia and the Middle East, and non-human primates in sub-Saharan Africa, Madagascar, and Asia (Gautret et al., 2010).

For UK citizens, pre-immunisation is recommended for travel to certain areas although not all travelers follow the recommended course of vaccination. The cost of vaccinations, as well as lack of information sought with respect to the potential threat from rabies, often precludes administration of vaccine. However, the...
importance of pre-immunization cannot be ignored. Furthermore, in cases where exposure to the virus is suspected, whether by bites, scratches or other means of exposure, individuals should seek medical advice without delay. This also applies to travelers in low risk areas as other infectious agents may be present, or the animal may have strayed from an area of endemicity. Indeed, even if the traveler exposed has been vaccinated, medical advice should be sought without delay. In addition to recommendations to seek medical advice, a few sensible precautions can be taken to avoid exposure in the first place. Contact with all wild or domestic animals should be avoided during travel. Simple first aid measures should also be taken if exposure is suspected. Washing the wound, if an animal bite has occurred, or site of exposure in the case of scratches or exchange of saliva to mucous membranes, with detergent for at least 5 min is strongly advised. If possible the area exposed to potential infection should also be doused in either iodine solution or, as iodine is often unavailable, a 40–50% alcohol solution where possible. These simple measures can greatly influence the outcome of exposure (Fooks et al., 2003b).

3. Concluding remarks

The implementation of strict legislation and quarantine in the UK has enabled the maintenance of a ‘rabies-free’ status and has ensured rapid containment of rabies infected animals that have entered the country. Furthermore, a complex framework exists that supports a strong contingency plan should the virus enter the country. However, there is no doubt that the risk of introduction into the UK of rabies and other exotic diseases remains. Across Europe a number of other human pathogens have been shown to be emerging that may, in the future, pose a greater risk to the UK population. Two cases of Lassa fever in travelers returning to the UK from Nigeria and Mali in February 2009 show a potential threat to the UK population. Whilst rare, Lassa fever is able to be transmitted between humans, and therefore, exposed individuals could be at risk (Atkin et al., 2009; Kitching et al., 2009). Health surveillance for individuals having had contact was necessary to ensure freedom from further disease.

Indeed, the development of sensitive molecular tools and increased surveillance of wildlife populations has highlighted a number of pathogens with zoonotic potential that pose a threat to human populations. The international travel of both humans and animals increases the risk of interaction with species harboring zoonotic disease and also the risk of global spread of disease in infected individuals that are unaware they have even been exposed. Recent ‘explosions’ of zoonotic pathogens highlight the continued risk to populations to emerging diseases, SARS coronavirus, pandemic and avian influenza virus, West Nile Fever virus and to a lesser extent Crimean Congo Hemorrhagic Fever virus have, in recent years, increased our awareness of the threat from zoonotic pathogens.

The control measures that have proved so effective in preventing rabies incursion need to be constantly reviewed and modified to ensure that they mitigate against potential exposure pathways. Routes of introduction are continually affected by increasing international travel and trade, movement of potential reservoir species and urbanization of wildlife. Novel control measures in response to new and emerging diseases will need to be considered in order to respond proportionately and effectively.

References

Aguilar-Setien, A., Loza-Rubio, E., Salas-Rojas, M., Brisseau, N., Cliquet, F., Pastoret, P.P., Rojas-Dotor, S., Tesoro, E., Kretschmer, R., 2005. Salivary excretion of rabies virus by healthy vampire bats. Epidemiol. Infect. 133 (3), 517–522.
Atkin, S., Anaraki, S., Gothard, P., Walsh, A., Brown, D., Gopal, R., Hand, J., Morgan, D., 2009. The first case of Lassa fever imported from Mali to the United Kingdom. February 2009. Euro Surveill 14 (10).
Banyard, A.C., Johnson, N., Voller, K., Hicks, D., Nunez, A., Hartley, M., Fooks, A.R., 2009. Repeated detection of European bat lyssavirus type 2 in dead bats found at a single roost site in the UK. Arch. Virol. 154 (11), 1847–1850.
Bourhy, H., Dacheux, L., Strady, C., Mailles, A., 2005. Rabies in Europe in 2005. Euro Surveill 10 (11), 213–216.
Dacheux, L., Larrous, F., Mailles, A., Boisseau, D., Delmas, O., Biron, C., Bouchier, C., Capek, I., Muller, M., Ilari, F., Lefranc, T., Raffi, F., Goudal, M., Bourhy, H., 2005. European bat Lyssavirus transmission among cats. Emerg. Infect. Dis. 15 (2), 280–284.
Fooks, A.R., Brooks, S.M., Johnson, N., McElhinney, L.M., Hutson, A.M., 2003a. European bat lyssaviuses: an emerging zoonosis. Epidemiol. Infect. 131 (3), 1029–1039.
Fooks, A.R., Johnson, N., Brooks, S.M., Parsons, C., McElhinney, L.M., 2003b. Risk factors associated with travel to rabies endemic countries. J. Appl. Microbiol. 94 (Suppl.), 315–365.
Fooks, A.R., McElhinney, L.M., Pounder, D.J., Finnegan, C.J., Mansfield, K., Johnson, N., Brooks, S.M., Parsons, G., White, K., Mcintyre, P.G., Nathwani, D., 2003c. Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. J. Med. Virol. 71 (2), 281–289.
Fooks, A., Roberts, D.H., Lynch, M., Hersteinsson, P., Runolfsson, H., 2004a. Rabies in the United Kingdom, in: OEIE (Ed.), Historical perspective of Rabies in Europe and the Mediterranean basin, OIE, France, pp. 25–32.
Fooks, A.R., McElhinney, L.M., Marston, D.A., Selden, D., Joliffe, T.A., Wakeley, P.R., Johnson, N., Brooks, S.M., 2004b. Identification of a European bat lyssavirus type 2 in a Daubenton’s bat found in Stanes, Surrey, UK. Vet. Rec. 155 (14), 434–435.
Fooks, A.R., Marston, D., Parsons, G., Earl, D., Dicker, A., Brooks, S.M., 2006. Isolation of EBLV-2 in a Daubenton’s bat (Myotis daubentoni) found in Oxfordshire. Vet. Rec. 159 (16), 534–535.
Fooks, A.R., Harkess, G., Goddard, T., Marston, D.A., McElhinney, L.M., Brown, K., Morgan, D., Paul, R., Thomas, P.J., Smith, B., 2008. Rabies virus in a dog imported to the UK from Sri Lanka. Vet. Rec. 162 (18), 598.
Freuling, C., Grossmann, E., Conraths, F.J., Schmaeitait, A., Kientj, A., Auer, E., Greiser-Wilkke, I., Milcke, T., 2008. First isolation of EBLV-2 in Germany. Vet. Microbiol. 131 (1–2), 26–34.
Gautret, P., Adehossi, E., Soula, G., Soavi, M.J., Delmotte, J., Rotival, Y., Brouqui, P., Parola, P., 2010. Rabies exposure in international travelers: do we miss the target? Int. J. Infect. Dis. 14 (3), e243–e246.
Harris, S.L., Brooks, S.M., Jones, G., Hutson, A.M., Fooks, A.R., 2006. Passive surveillance (1987 to 2004) of United Kingdom bats for European bat lyssaviuses. Vet. Rec. 159 (14), 439–446.
Harris, S.L., Mansfield, K., Marston, D.A., Johnson, N., Pajamo, K., O’Brien, N., Black, C., McElhinney, L.M., Fooks, A.R., 2007. Isolation of European bat lyssavirus type 2 from a Daubenton’s bat (Myotis daubentoni) found in Shropshire. Vet. Rec. 161 (11–12), 384–386.
Harris, S.L., Aegerter, J.N., Brooks, S.M., McElhinney, L.M., Jones, G., Smith, G.C., Fooks, A.R., 2009. Targeted surveillance for European bat lyssaviuses in English bats (2003–06). J. Wildl. Dis. 45 (4), 1030–1041.
Horton, D.L., Voller, K., Haxton, B., Johnson, N., Leech, S., Goddard, T., Wilson, C., McElhinney, L.M., Fooks, A.R., 2009. European bat lyssavirus type 2 in a Daubenton’s bat in Scotland. Vet. Rec. 165 (13), 383–384.
Hunter, M., Johnson, N., Hedderwick, S., McHugh, C., Lowry, K., McConville, J., Herron, B., McCaughy, S., Marston, D., Goddard, T., Goharriz, H., Voller, K., Solomon, T., Willoughby, R.E., Fooks, A.R., 2010. Immunovirological correlates in human rabies. OIE, France, pp. 25–32.
Jakaeva-Vijoljan, M., Lilley, T., Kyhoreinoin, E.M., Huovilainen, A., 2010. First encounter of European bat lyssavirus type 2 (EBLV-2) in a bat in Finland. Epidemiol. Infect., 1–5.
A.C. Banyard et al. / Virus Research 152 (2010) 79–84

Johnson, N., Brookes, S.M., Fooks, A.R., Ross, R.S., 2005. Review of human rabies cases in the UK and in Germany. Vet. Rec. 157 (22), 715.

Johnson, N., Lipscumb, D.W., Stott, R., Gopal Rao, G., Mansfield, K., Smith, J., McElhinney, L., Fooks, A.R., 2002. Investigation of a human case of rabies in the United Kingdom. J. Clin. Virol. 25 (3), 351–356.

Johnson, N., Selden, D., Parsons, G., Healy, D., Brookes, S.M., McElhinney, L.M., Hutson, A.M., Fooks, A.R., 2003. Isolation of a European bat lyssavirus type 2 from a Daubenton’s bat in the United Kingdom. Vet. Rec. 152 (13), 383–387.

Kitching, A., Addiman, S., Cathcart, S., Bishop, L., Krahe, D., Nicholas, M., Coakley, J., Lloyd, G., Brooks, T., Morgan, D., Turbitt, D., 2009. A fatal case of Lassa fever in London. Journal of Medical Virology. 14 (6).

Lumio, J., Hillibom, M., Roine, R., Ketton, L., Haltia, M., Valle, M., Neuvonen, E., Lahdevirta, J., 1986. Human rabies of bat origin in Europe. Lancet 1 (8477), 378.

McColl, K.A., Tordo, N., Aguilar-Setién, A.A., 2000. Bat lyssavirus infections. Rev. Sci. Tech. 19 (April (1)), 177–196.

Muller, T., Cox, J., Peter, W., Schafer, R., Johnson, N., McElhinney, L.M., Geue, J.L., Tjornehoj, K., Fooks, A.R., 2004. Spill-over of European bat lyssavirus type 1 into a stone marten (Martes foina) in Germany. J. Vet. Med. B Infect. Dis. Vet. Public Health 51 (2), 49–54.

Muller, T., Johnson, N., Freuling, C.M., Fooks, A.R., Sethorst, T., Vos, A., 2007. Epidemiology of bat rabies in Germany. Arch. Virol. 152 (2), 273–288.

Pajamaki, K., Harkess, G., Goddard, T., Marston, D., McElhinney, L., Johnson, N., Fooks, A.R., 2008. Isolation of European bat lyssavirus type 2 (EBLV-2) in a Daubenton’s bat in the UK with a minimum incubation period of 9 months. Rabies Bull. Eur. J. 32, 6–7.

Perez-Jorda, J.L., Ibanez, C., Munoz-Cervera, M., Teller, A., 1995. Lyssavirus in Eptesicus serotinus (Chiroptera: Vespertilionidae). J. Wildl. Dis. 31 (3), 372–377.

Ronsholt, L., 2002. A new case of European bat lyssavirus (EBL) infection in Danish sheep. Rabies Bull. Eur. J. 26 (2).

Selemon, M.A., Tatarov, A.G., Botvinkin, A.D., Klueva, E.V., Kulikova, L.G., Khsimatullina, M.A., 1989. Rabies-related Yuli virus, identification with a panel of monoclonal antibodies. Acta Virol. 33 (6), 542–546.

Serra Cobo, J., Amengual, R., Abellan, C., Bourhy, H., 2002. European bat lyssavirus infection in Spanish bat populations. Emerg. Infect. Dis. 8 (4), 413–420.

Solomon, T., Marston, D., Mallewa, M., Felton, T., Shaw, S., McElhinney, L.M., Das, K., Mansfield, K., Wainwright, J., Kwong, G.N., Fooks, A.R., 2005. Paralytic rabies after a two week holiday in India. BMJ 331 (Sep 3, 7515), 501–503.

Smith, J., McElhinney, L., Parsons, G., Brink, N., Doherty, T., Agranoff, D., Miranda, M.E., Fooks, A.R., 2003. Case report: rapid ante-mortem diagnosis of a human case of rabies imported into the UK from the Philippines. J. Med. Virol. 69 (1), 150–155.

Tjornehoj, K., Ronsholt, L., Fooks, A.R., 2004. Antibodies to EBLV-1 in a domestic cat in Denmark. Vet. Rec. 155 (18), 571–572.

Van der Poel, W.H., Van der Heide, R., Verstraten, E.R., Takumi, K., Lina, P.H., Kramps, J.A., 2005. European bat lyssaviruses, The Netherlands. Emerg. Infect. Dis. 11 (12), 1854–1859.

van Thielen, P.P., van den Hoek, J.A., Eftimov, F., Tepaske, R., Zaaier, H.J., Spanjaard, L., de Boer, H.F., van Doornum, G.J., Schutten, M., Osterhaus, A., Kager, P.A., 2008. Fatal case of human rabies (Duvemhage virus) from a bat in Kenya: The Netherlands, December 2007. Euro Surveill. 13 (2).

Vazquez-Moron, S., Juste, J., Ibanez, C., Ruiz-Villamor, E., Avellon, A., Vera, M., Echevarria, J.A., 2008. Endemic circulation of European bat lyssavirus type 1 in serotine bats, Spain. Emerg. Infect. Dis. 14 (8), 1263–1266.

Whitby, J.E., Heaton, P.R., Black, E.M., Woolridge, M., McElhinney, L.M., Johnstone, P., 2000. First isolation of a rabies-related virus from a Daubenton’s bat in the United Kingdom. Vet. Rec. 147 (14), 385–388.